Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New drugs in preclinical and early stage clinical development in the treatment of heart failure
Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Investigational Drugs (2018) Vol. 28, Iss. 1, pp. 51-71
Closed Access | Times Cited: 22

Showing 22 citing articles:

Resveratrol and endothelial function: A literature review
Negin Parsamanesh, Arghavan Asghari, Saeed Sardari, et al.
Pharmacological Research (2021) Vol. 170, pp. 105725-105725
Closed Access | Times Cited: 139
Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver
Daniele Mancardi, Mariarosa Mezzanotte, Elisa Arrigo, et al.
Antioxidants (2021) Vol. 10, Iss. 12, pp. 1864-1864
Open Access | Times Cited: 120
Natural bioactive products as promising therapeutics: A review of natural product-based drug development
Chetan Aware, Devashree N. Patil, Suresh S. Suryawanshi, et al.
South African Journal of Botany (2022) Vol. 151, pp. 512-528
Closed Access | Times Cited: 87
Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Pran Kishore Deb, Satyendra Deka, Pobitra Borah, et al.
Current Pharmaceutical Design (2019) Vol. 25, Iss. 25, pp. 2697-2715
Closed Access | Times Cited: 49
Glycolysis Inhibition Alleviates Cardiac Fibrosis After Myocardial Infarction by Suppressing Cardiac Fibroblast Activation
Zhi-Teng Chen, Qing‐Yuan Gao, Maoxiong Wu, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 40
LncRNA HOX transcript antisense RNA mitigates cardiac function injury in chronic heart failure via regulating microRNA‐30a‐5p to target KDM3A
Xiaoyun Zhang, Yakun Gao, Hongyu Wu, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 5, pp. 1473-1485
Open Access | Times Cited: 20
Targeting regulatory T cells for cardiovascular diseases
Xinting Wang, Hua Zhou, Qian Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
ARNI in cardiovascular disease: current evidence and future perspectives
Pramod K. Kuchulakanti
Future Cardiology (2020) Vol. 16, Iss. 5, pp. 505-515
Closed Access | Times Cited: 32
LuQi Formula Ameliorates Pressure Overload-induced Heart Failure by Regulating Macrophages and Regulatory T cells
Xinting Wang, Qian Liu, Peipei Cheng, et al.
Phytomedicine (2025), pp. 156527-156527
Closed Access
Current state of heart failure treatment: are mesenchymal stem cells and their exosomes a future therapy?
Chengqian Chen, Wentao Zhong, Hao Zheng, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Non-Canonical Allostery in Cyclic Nucleotide Dependent Kinases
Mariia Khamina, Karla Martinez Pomier, Madoka Akimoto, et al.
Journal of Molecular Biology (2022) Vol. 434, Iss. 17, pp. 167584-167584
Closed Access | Times Cited: 15
Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?
Piero Pollesello, Tuvia Ben Gal, Dominique Béttex, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 11, pp. 1834-1834
Open Access | Times Cited: 18
Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure
María Tamayo, Laura Martín‐Nunes, Almudena Val‐Blasco, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 14, pp. 3273-3290
Open Access | Times Cited: 16
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview
Diego Dal Ben, Catia Lambertucci, Michela Buccioni, et al.
Pharmaceuticals (2019) Vol. 12, Iss. 4, pp. 150-150
Open Access | Times Cited: 15
Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function
Zoltán Szabó, Laura Vainio, Ruizhu Lin, et al.
The FASEB Journal (2020) Vol. 34, Iss. 8, pp. 9911-9924
Open Access | Times Cited: 11
Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists
Zulan Pi, James A. Johnson, Wei Meng, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 11, pp. 1766-1772
Open Access | Times Cited: 8
A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury
Jing Liu, Qingshu Meng, Xiaoting Liang, et al.
International Journal of Molecular Medicine (2019)
Open Access | Times Cited: 8


ANALES RANM (2021) Vol. 138, Iss. 138(01)
Open Access | Times Cited: 5
The scientific targets: the myocardium, the vasculature and the body’s response to heart failure
Rafael Vidal-Pérez, Ewa A. Jankowska
Global Cardiology (2024) Vol. 2, Iss. 1
Open Access
The Scientific Targets: the Myocardium, the Vasculature and the Body’s Response to Heart Failure
Rafael Vidal-Pérez, Ewa A. Jankowska
International Cardiovascular Forum Journal (2019) Vol. 17
Open Access
Floralozone plays a role in heart failure treatment by down-regulating Vascular Endothelial Growth Factor Receptor 1 Expression
Ya-ling Yin, Yaqi Guo, Hong-yan Hou, et al.
Research Square (Research Square) (2022)
Open Access
Development of new drugs for treatment of heart failure (adventures, disasters and joys)
Juan Tamargo
ANALES RANM (2021) Vol. 138, Iss. 138(01), pp. 44-51
Open Access
Page 1

Scroll to top